Title:
TREATMENT OF FIBROSIS USING FXR LIGANDS
Document Type and Number:
WIPO Patent Application WO2005089316
Kind Code:
A3
Abstract:
The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
Inventors:
FIORUCCI STEFANO (IT)
PELLICCIARI ROBERTO (IT)
PRUZANSKI MARK (US)
PELLICCIARI ROBERTO (IT)
PRUZANSKI MARK (US)
Application Number:
PCT/US2005/008575
Publication Date:
April 06, 2006
Filing Date:
March 14, 2005
Export Citation:
Assignee:
INTERCEPT PHARMACEUTICALS INC (US)
FIORUCCI STEFANO (IT)
PELLICCIARI ROBERTO (IT)
PRUZANSKI MARK (US)
FIORUCCI STEFANO (IT)
PELLICCIARI ROBERTO (IT)
PRUZANSKI MARK (US)
International Classes:
(IPC1-7): A61K31/56
Domestic Patent References:
| WO2004048349A1 | 2004-06-10 | |||
| WO2002072598A1 | 2002-09-19 | |||
| WO2003043581A2 | 2003-05-30 |
Other References:
FIORUCCI S.: "The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells By FXR and Protects Against Liver Fibrosis", GASTROENTEROLOGY, vol. 127, 2004, pages 1497 - 1512, XP002994584
PELLICCIARI R.: "6Alpha-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 17, August 2002 (2002-08-01), pages 3569 - 3572, XP002287455
See also references of EP 1734970A4
PELLICCIARI R.: "6Alpha-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 17, August 2002 (2002-08-01), pages 3569 - 3572, XP002287455
See also references of EP 1734970A4
Download PDF:
Previous Patent: METHODS AND COMPOSITIONS RELATED TO SKCG-1, A TUMOR SUPPRESSOR GENE
Next Patent: IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS
Next Patent: IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS